Dr. Harada, Chiarman and Head or R&D, will present the recent progress on preclinical study of UI-102 at the upcoming the 5th Macrophage-directed Therapies Summit in Boston, USA on November 13 to 15.
The title is “UI-102, a TLR7/8 agonist encapsulated in cholesteryl pullulan nanoparticle targeting tumor-associated macrophages via binding to DC-SIGN, elicits potent anti-tumor immunity without severe side effect.”